MEDIFOX DAN
2022
$1.0B
ResMed
Medical Devices & Digital HealthFounded 1989- HQ today: San Diego, California, United States
Reviewed by Swet Parvadiya
Company data updated: November 2026
Acquisitions
ResMed Acquisitions
4
Major Deals Covered
$2.8B
Disclosed Deal Value
What are ResMed's biggest acquisitions?
ResMed's largest disclosed acquisition here is Brightree LLC for $800 in 2016. This page covers 4 major deals from 2016 to 2022, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Brightree LLC ($800)
- First deal
- 2016
- Most recent
- 2022
| Company | Year | Price | Purpose |
|---|---|---|---|
| 2022 | Undisclosed | German provider of out-of-hospital software solutions for ambulatory nursing, elderly care, and therapists. | |
| 2018 | Undisclosed | Long-term post-acute care EHR and senior living practice management software. | |
| 2016 | Undisclosed | Cloud-based billing, patient resupply, and business management software for home medical equipment. | |
| 2019 | Undisclosed | Digital sensor attachments for inhalers monitoring COPD and asthma medication adherence. |
- What companies has ResMed bought?
- Major acquisitions by ResMed documented here include Brightree LLC (2016), MatrixCare (2018), Propeller Health (2019) and MEDIFOX DAN (2022).
- What is ResMed's most recent acquisition?
- The most recent ResMed acquisition documented here is MEDIFOX DAN, in 2022, for $1.
Propeller Health
2019
$225M
MatrixCare
2018
$750M
Brightree LLC
2016
$800M
ResMed's Growth & Acquisition Strategy
Under CEO Mick Farrell, ResMed is pursuing four key strategic growth drivers: (1) Expanding the Global Sleep Apnea Funnel: With an estimated 936 million people worldwide suffering from sleep apnea and over 80% remaining undiagnosed, ResMed is partnering with consumer health leaders (Apple, Samsung) and sleep testing innovators (NightOwl) to streamline home sleep apnea testing; (2) Accelerating AirSense 11 Global Conversion: Completing the worldwide rollout of the AirSense 11 platform, featuring enhanced digital coaching and touchscreens, driving device upgrades; (3) Expanding Post-Acute SaaS Platform: Cross-selling Brightree and MatrixCare practice management software to nursing homes, home health agencies, and outpatient providers; and (4) Harnessing Generative AI for Therapy Adherence: Deploying AI algorithms within the myAir patient app to provide customized behavioral nudges, troubleshooting air leaks and mask fit to maximize nightly compliance.
How ResMed Makes Money
ResMed operates a highly lucrative, resilient razor-and-blade medtech business model reinforced by high-margin software subscriptions: (1) Connected Devices (~53% of revenue / ~$2.5B), manufacturing premium CPAP, APAP, and bilevel flow generators (AirSense 11, AirCurve 11, AirMini) sold to home medical equipment (HME) suppliers and healthcare systems; (2) Masks & Consumables (~35% of revenue / ~$1.6B), delivering high-margin recurring cash flows from nasal, full-face, and minimalist nasal pillow masks (AirFit F30i, N30i, P10), silicone cushions, headgear, and humidification tubing that patients replace every 3 to 6 months; and (3) Out-of-Hospital SaaS Solutions (~12% of revenue / ~$560M), monetizing cloud subscription platforms including Brightree (HME billing and practice management), MatrixCare (long-term post-acute EHR), and MEDIFOX DAN (European ambulatory care software). ResMed generates gross margins near 59% and over $1.3 billion in annual operating cash flow.
ResMed Acquisitions FAQ
What is ResMed's general approach to M&A and acquisitions?
ResMed pursues a disciplined, strategic M&A approach focused on acquiring proprietary technologies, expanding customer distribution reach, and unlocking operational cost synergies rather than pursuing unselective scale.
What were some of the most transformative acquisitions completed by ResMed?
Transformative transactions in ResMed's history include pivotal mergers and acquisitions that secured key regional footprints, consolidated core market share, and brought proprietary software intellectual property in-house.
How does ResMed successfully integrate acquired companies?
ResMed deploys dedicated integration teams to harmonize core software stacks, align regulatory compliance systems, and unite company cultures while preserving entrepreneurial agility.
Does ResMed divest non-core corporate assets?
Yes, ResMed periodically evaluates its corporate portfolio, strategically divesting non-core or non-strategic assets to redeploy capital into high-margin core operational divisions.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore ResMed
Core profile pages, founders and related research hubs for this company.